Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of trastuzumab resistance. AXL orchestrates epithelial-to-mesenchymal transition an...

Descripción completa

Detalles Bibliográficos
Autores principales: Adam-Artigues, Anna, Arenas, Enrique J., Martínez-Sabadell, Alex, Brasó-Maristany, Fara, Cervera, Raimundo, Tormo, Eduardo, Hernando, Cristina, Martínez, María Teresa, Carbonell-Asins, Juan, Simón, Soraya, Poveda, Jesús, Moragón, Santiago, Zazo, Sandra, Martínez, Débora, Rovira, Ana, Burgués, Octavio, Rojo, Federico, Albanell, Joan, Bermejo, Begoña, Lluch, Ana, Prat, Aleix, Arribas, Joaquín, Eroles, Pilar, Cejalvo, Juan Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122332/
https://www.ncbi.nlm.nih.gov/pubmed/35594351
http://dx.doi.org/10.1126/sciadv.abk2746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122332/
https://www.ncbi.nlm.nih.gov/pubmed/35594351
http://dx.doi.org/10.1126/sciadv.abk2746

Ejemplares similares